Global Health Technologies Coalition

Matthew Robinson, MA

Policy and Advocacy Officer

Matthew manages the coalition’s multilateral policy analysis and advocacy work. He develops and implements outreach strategies to the various United Nations agencies and other multilateral organizations to ensure that the coalition is advocating a consistent position with all global health R&D stakeholders.

Matthew has a background in global health diplomacy. Prior to joining GHTC he served for four years in the Multilateral Diplomacy section of the Office of the US Global AIDS Coordinator at the US Department of State. As the Advisor for Multilateral Diplomacy, he led policy analysis and development, as well as assisting in outreach and negotiation efforts on a number of key Global Fund issues, with primary responsibility for those arising in the Policy and Strategy Committee. He has held positions with the Global Fund to Fight AIDS, TB and Malaria, as well as UNICEF, in addition to interning with the Population Council and the Woodrow Wilson International Center for Scholars.

Matthew received his MA in Global Human Development (with a specialization in global health systems) from Georgetown University School of Foreign Service, and his BA in Philosophy (with a concentration in systems of logical analysis) from Bates College. For a number of years he held a full racing license and in his free time still enjoys long drives on winding country roads.

Articles Written by Matthew

Flickr/United States Mission Geneva, Eric Bridiers
WHO EB moves forward actions on budget, access to medicines, and AMR R&D

The 2019 global health multilateral calendar kicked off as it always does with the World Health Organization (WHO) Executive Board (EB) meeting in late January in Geneva. This year’s session featured a packed agenda with significant implications for research and development.

Read More
PATH/Georgina Goodwin
G20 health ministers meet: The good, the bad, and the unknown for health R&D

Health ministers of the G20 nations, representing the world’s leading economies, met earlier this month in Mar del Plata, Argentina to chart a course of action on global health for the upcoming year.

Read More
WHO/L. Cipriani
WHA Roundup: Incremental steps forward on access and TB takes the limelight

What global health research advocates need to know about the 71st World Health Assembly (WHA).

Read More
Pan American Health Organization
What to watch at WHA 71

The 71st session of the World Health Assembly will see a number of debates that could impact global health R&D. Here is is what you need to know.

Read More
GHTC/Matt Robinson
WHO Executive Board approves actions on access to medicine and intellectual property

Last week’s World Health Organization (WHO) Executive Board meeting featured agenda items on access to medicines and intellectual property. We cover how debates on these items shook out:

Read More
GHTC/Taylor Capizola
Overheard at UNGA: Innovation paves path to universal health coverage

A busy week at the 72nd United Nations General Assembly winds to a close with key discussions surrounding the global economic returns of health R&D.

Read More
PATH/Eric Becker
G20 makes first-ever pledge to support R&D to combat global health challenges

Following a sustained advocacy campaign by GHTC and our partners, global health R&D has been featured, for the first time, as part of the G20 declaration. The declaration, published on July 8, includes efforts for R&D to combat antimicrobial resistance and potentially pandemic diseases.

Read More
WHO/L. Cipriani
WHA Roundup: a new WHO head, the demise of an R&D pooled fund, and the access debate rages on

The 70th World Health Assembly (WHA) winds to a close with key decisions that will shape the future of the World Health Organization (WHO) and the landscape for global health R&D.

Read More
CDC/Dr. Scott Smith
G20 health ministers pledge support for R&D to combat antimicrobial resistance, pandemic threats

Health ministers from G20 nations, meeting for the first time, pledged to work together to combat antimicrobial resistance and improve pandemic preparedness, emphasizing the critical role R&D plays in confronting these global challenges.

Read More
U.S. Mission Photo/Eric Bridiers
Who will lead WHO and what to watch at WHA

With the 70th World Health Assembly (WHA) commencing next week, GHTC takes a look at what's on the agenda and how it could impact global health R&D.

Read More
GHTC/Matt Robinson
WHO Executive Board meeting closes with three shortlisted candidates to lead WHO and R&D issues added to WHA agenda

The 140th session of the World Health Organization (WHO) Executive Board closed last week with a shortlist of  three candidates for the WHO Director General position and progress on key global health R&D issues.

Read More
PATH/Patrick McKern
WHO begins process to establish an essential diagnostics list following calls by GHTC and partners

We asked. WHO listened. The World Health Organization (WHO) took the first step toward establishing an essential diagnostics list, releasing a proposal outling how it plans to develop and operationalize the list by early 2019.

Read More
The world keeps turning: WHO’s 140th Executive Board meeting begins

With the 140th World Health Organization (WHO) Executive Board meeting commencing this week, GHTC takes a look at what's on the agenda and how it could impact global health R&D.

Read More
PATH/Gena Morgan
Why GHTC is joining the call for an essential diagnostics list

An essential diagnostic list list in a smart, cost-effective idea that could advance diagnostic R&D and access.

Read More
UN Photo/Joao Araujo Pinto
How did global health R&D fare at UNGA 71?

The 71st United Nations General Assembly (UNGA) concluded this week. Breakthroughs gives a synopsis of the key global health R&D issues discussed at the assembly and what actions were taken.

Read More
GHTC/Matthew Robinson
The world commits to the AMR fight

At the United Nations General Assembly, world leaders made an unprecedented collective commitment to fighting the growing problem of antimicrobial resistance. GHTC and Global Health Council analyze what that commitment entails, why it matters, and the importance of what happens next.

Read More
UN Photo/Loey Felipe
UNGA 2016: The world wakes up to AMR

The midtown Manhattan mayhem begins with the opening of the 71st United Nations General Assembly. GHTC preview the global health policy issues that will be discussed at this year's assembly.

Read More
GHTC/Matthew Robinson
One week of WHA, extensive debate, and two key R&D decisions

As happens every May, the World Health Organization’s (WHO) highest governing body, the World Health Assembly (WHA), met last week for its 69th annual meeting in Geneva, Switzerland. The agenda was the most packed in recent memory, consisting of more than 70 discussion items, many of which were controversial. Despite the lengthy agenda and difficult conversations, the WHA made two key decisions impacting global health research and development (R&D).

Read More
WHO's doing WHA for the 69th time next week!

This coming week the “who’s who” of the global health community (as well as some much more modest global health advocates such as your humble author) will make the annual trek to Geneva, Switzerland, for the 69th World Health Assembly (WHA), where World Health Organization (WHO) member states will collectively decide WHO’s plans for the coming year.

Read More
Better together? Five takeaways on the proposal for a WHO pooled fund

Last week, GHTC convened a panel of experts to dissect and discuss a proposal for pooled funding for global health research and development (R&D).

Read More
WHO says “no thanks” to the private sector

There’s an old adage about political negotiating: “You need to be in the room when things are happening if you want to have an impact.”

Read More
WHO’s Doing What?

With the New Year underway, GHTC is looking forward to a busy spring of multilateral organization meetings—with a number of them impacting global health research and development (R&D). First on the agenda is the World Health Organization (WHO) Executive Board (EB) meeting on January 25–30 in Geneva, where the EB will receive updates on a number of topics and make important decisions, particularly around how to proceed with the next steps of the Consultative Expert Working Group on Research and Development: Financing and Coordination (CEWG) process.

Read More



Emily Conron

Policy and Advocacy Officer

Learn More about Emily

Steering Committee


Rachel M. Cohen, MA

Regional Executive Director, North America

Drugs for Neglected Diseases initiative

Learn More about Rachel

Jodie Curtis

Washington Representative

American Society of Tropical Medicine and Hygiene

Learn More about Jodie

Kevin Fisher

Director of Policy, Data & Analytics


Learn More about Kevin

Karen A. Goraleski, MA

Executive Director

American Society of Tropical Medicine and Hygiene

Learn More about Karen

Heather Ignatius, MA

Director, US and Global Advocacy


Learn More about Heather

Sharyn Tenn, MA

Senior Director, External Affairs and Product Access

International Partnership for Microbicides

Learn More about Sharyn